Seeking an optimal eradication therapy for Helicobacter pylori infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori.Helicobacter · 2014
   Trial
2. Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in RefractoryFrontiers in microbiology · 2022
   Article
3. Cost-effectiveness analysis of two routine therapeutic methods forGastroenterology and hepatology from bed to bench · 2021
   Article
4. Comparison ofGastroenterology and hepatology from bed to bench · 2018
   Article
5. Helicobacter pylori Eradication Therapy: Current Availabilities.ISRN gastroenterology · 2012
   Article

Corrections and comments

• Comment on
  Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.2009
• Comment on
  Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as